IMAGING CHARACTERISTICS OF HEPATITIS CELL CANCER ASSOCIATED WITH TRANSARTERIAL CHEMOEMBOLIZATION REFRACTORINESS
Main Article Content
Abstract
Objectives: Comparison and evaluation of imaging characteristics of hepatocellular carcinoma related to refractoriness of transarterial chemoembolization (TACE). Methods: A descriptive cross-sectional, retrospective study was conducted on 71 patients diagnosed with hepatocellular carcinoma and treated with at least two initial chemoembolization procedures from January 2022 to January 2024 at the Radiology Center of Bach Mai Hospital. The patients were divided into two groups: TACE-resistant and non-TACE-resistant. A comparison and evaluation of demographic, laboratory, and imaging characteristics between the two groups were conducted to identify risk factors for TACE refractoriness. Results: Out of 71 patients, 31 exhibited TACE resistance. Characteristics such as age, gender, risk factors for cirrhosis, and cirrhosis status according to the Child-Pugh classification were not associated with TACE refractoriness. Logistic regression showed that bilobar tumor distribution (OR=4.049, 95% CI [1.323; 9.267], p = 0.0018), >1 tumor (OR=4.052, 95% CI [1.052; 5.266], p = 0.043), and beyond the up-to-7 criteria (OR=3.555, 95% CI [1.201; 7.284], p = 0.026) were associated with TACE refractoriness, with a model predictive accuracy of 74.6%. Conclusion: Imaging characteristics such as bilobar tumor distribution, more than 3 tumors, and beyond up-to-7 criteria are independent risk factors that increase the likelihood of TACE refractoriness
Keywords
hepatocellular carcinoma, transarterial chemoembolization, TACE refractoriness
Article Details
References
2. Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology. 2018;69(1):182-236. doi:10.1016/j.jhep.2018.03.019
3. Wang TC, An TZ, Li JX, Zhang ZS, Xiao YD. Development and Validation of a Predictive Model for Early Refractoriness of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. Front Mol Biosci. 2021;8:633590. doi:10.3389/fmolb.2021.633590
4. Kudo M, Kawamura Y, Hasegawa K, et al. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer. 2021;10(3):181-223. doi:10.1159/000514174
5. Asafo-Agyei KO, Samant H. Hepatocellular Carcinoma. In: StatPearls. StatPearls Publishing; 2024. Accessed August 7, 2024. http://www.ncbi.nlm.nih.gov/books/NBK559177/
6. Yang C, Luo Y gen, Yang H cai, Yao Z hang, Li X. Effects of Early TACE Refractoriness on Survival in Patients with Hepatocellular Carcinoma: A Real-World Study. Journal of Hepatocellular Carcinoma. 2022;9:621-631. doi:10.2147/JHC.S373112
7. Zou ZM, An TZ, Li JX, Zhang ZS, Xiao YD, Liu J. Predicting early refractoriness of transarterial chemoembolization in patients with hepatocellular carcinoma using a random forest algorithm: A pilot study. J Cancer. 2021;12(23):7079- 7087. doi:10.7150/jca.63370
8. Koroki K, Ogasawara S, Ooka Y, et al. Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. Liver Cancer. 2020;9(5):596-612. doi:10.1159/000508809